GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (FRA:3XI) » Definitions » Asset Turnover

Biomind Labs (FRA:3XI) Asset Turnover : 0.00 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Biomind Labs's Revenue for the three months ended in Sep. 2023 was €0.00 Mil. Biomind Labs's Total Assets for the quarter that ended in Sep. 2023 was €0.13 Mil. Therefore, Biomind Labs's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Biomind Labs's annualized ROE % for the quarter that ended in Sep. 2023 was 48.46%. It is also linked to ROA % through Du Pont Formula. Biomind Labs's annualized ROA % for the quarter that ended in Sep. 2023 was -377.60%.


Biomind Labs Asset Turnover Historical Data

The historical data trend for Biomind Labs's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Asset Turnover Chart

Biomind Labs Annual Data
Trend Dec21 Dec22
Asset Turnover
- -

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biomind Labs's Asset Turnover

For the Biotechnology subindustry, Biomind Labs's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Asset Turnover falls into.



Biomind Labs Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Biomind Labs's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (2.237+0.084)/ 2 )
=0/1.1605
=0.00

Biomind Labs's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=0/( (0.102+0.148)/ 2 )
=0/0.125
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Biomind Labs  (FRA:3XI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Biomind Labs's annulized ROE % for the quarter that ended in Sep. 2023 is

ROE %**(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-0.472/-0.974
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.472 / 0)*(0 / 0.125)*(0.125/ -0.974)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.1283
=ROA %*Equity Multiplier
=-377.60 %*-0.1283
=48.46 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Biomind Labs's annulized ROA % for the quarter that ended in Sep. 2023 is

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-0.472/0.125
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.472 / 0)*(0 / 0.125)
=Net Margin %*Asset Turnover
= %*0
=-377.60 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Biomind Labs Asset Turnover Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs (FRA:3XI) Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs (FRA:3XI) Headlines

No Headlines